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ABSTRACT 
EXPRESSION OF ADIPOCYTE/MACROPHAGE FATTY ACID BINDING 
PROTEIN PROMOTES TUMOR GROWTH AND METASTASIS 
Ashley Triplett 
April 26, 2012 
It has been estimated that 30% of all cancer deaths in the U.S. are associated 
with obesity. It is well-established that obesity promotes low-grade chronic 
inflammation, however the mechanisms by which obesity-induced chronic 
inflammation may promote cancer development and progression are not well-
defined. Fatty acid binding proteins (FABPs), which are intracellular lipid 
chaperones, regulate both metabolic and inflammatory pathways. Of the nine 
FABP family members, adipocyte/macrophage-FABP (A-FABP) has been found 
to be highly expressed in macrophages in both mice and humans and its 
expression is increased in response to a high-fat diet. In the present study we 
examined the influence of A-FABP expression on tumor growth and metastasis in 
mice under conditions of normal or high-fat feeding. Wild-type (WT) and A-FABP 
knockout (A-FABP KO) mice were placed on a normal or high-fat diet prior to the 
injection of Lewis Lung Carcinoma cells (LLl2). When fed a normal diet, LLl2 
tumor metastasis was significantly reduced in A-FABP KO mice relative to WT 
mice, whereas tumor growth in A-FABP KO and WT mice was similar. However, 
a high fat diet resulted in a Significant increase in both tumor growth and 
vi 
metastasis in WT, but not A-FABP KO mice. Western blot and RT-PCR analysis 
demonstrated that tumor-infiltrating macrophages isolated from A-FABP KO mice 
on a normal or high-fat diet have reduced pro-inflammatory cytokine production, 
NF-kB activation, and decreased expression of metastasis-promoting proteins, 
MMP-9 and MMP-12. Immunohistochemical analysis showed reduced 
expression of CD31 in tumors from A-FABP KO mice on either diet compared to 
tumors from WT mice. Taken together, our data suggest that A-FABP contributes 
to tumor growth and metastasis and implicate A-FABP as a link between fat 
consumption and cancer progression. 
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INTRODUCTION 
General Background 
Obesity is an increasing problem amongst children and adults in the 
United States (Figure 1) and it is estimated that 30% of all cancer deaths in the 
U.S. are associated with obesity. Obesity has been shown to increase the risk, 
incidence, and mortality of several types of cancers including those of the breast, 
prostate, colon, pancreas, kidney, liver, esophagus, endometrium, and many 
others [1, 2]. It is well established that obesity promotes systemic low-grade 
chronic inflammation, and chronic inflammation is also involved in the 
pathogenesis of 15-20% of human tumors. The main inflammatory component 
both within the tumor and the adipose tissue of obese humans are macrophages 
[3-5]. In an obese state, there is increased recruitment and accumulation of 
macrophages into the adipose tissue. In lean mice, 10-15% of cells in the 
adipose tissue express the macrophage marker F4/S0, whereas 45-60% of cells 
are F4/S0+ in the adipose tissue of obese mice [6, 7]. Adipose tissue 
macrophages exhibit a polarized pro-inflammatory phenotype with increased 
production of various inflammatory cytokines such as interleukin-6 (IL-6) and 
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tumor necrosis factor-a (TNF-a), leading to a chronic inflammatory state. This, in 
turn, promotes the onset and progression of many diseases that collectively 
make up metabolic syndrome, including atherosclerosis, diabetes, and insulin 
resistance. In cancer, macrophages secrete a variety of growth factors, 
chemokines, and cytokines that potentiate inflammation, tumor cell growth, 
proliferation-and survival, angiogenesis, as well as invasion and metastasis [8-
12]. However, the mechanism(s) by which obesity-induced chronic inflammation 
promotes cancer development and progression is not well defined. Herein, we 
demonstrate that adipocyte-fatty acid binding protein (A-FABP), which is 
expressed in macrophages and can influence their inflammatory phenotype, 
serves as a link between obesity and cancer via impacting the functional 
phenotype of tumor-infiltrating macrophages (Figure 2). 
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Obesity Trends A.mong U.S. Adults 
(+BMI ~30. or - 30 Ibs. overweight fo·r S' 4" person) 
Figure 1. Statisical description of obesity trends among adults in the United 
States. The Center for Disease Control and Prevention (CDC) conducted a study 
where they followed obesity trends in U.S. adults over a 24-year period. In 1987, 
the U.S. was a relatively lean country with less than 14% of state populations 
considered to be obese. By 2009, however, majority of U.S. state populations 
had 25% or more adults that were obese. Adapted from Behavioral Risk Factor 
Surveillance System, CDC. 
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Figure 2. The role of macrophages in obesity·related diseases and cancer. 
Macrophages have a well-documented role in both obesity and cancer. Through 
the secretion of various cytokines, growth factors, fatty acids, and chemokines, 
macropahges promote the progression and development of several obesity-
related diseases, including atherosclerosis and type 2 diabetes, as well as 
cancer. However the link between obesity-induced chronic inflammation and 
cancer progression remains elusive. Here, FABP expression in macrophages 
may serve as a link between a high fat diet and the progression of cancer. 
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Macrophage Function and Plasticity 
The mononuclear phagocyte system is a subpopulation of immune cells 
that are generated from hematopoietic stem cells located in the bone marrow. 
Monocytes are released into the blood circulation and seed various tissues 
throughout the body. During inflammation and steady state, although the latter is 
less efficient, monocytes differentiate into macrophages or dendritic cells [13, 
14]. Macrophages are highly versatile, multi-functional cells that are involved in 
the inflammatory response as well as common "janitorial" roles where they clear 
the interstitial environment of waste material [14, 15]. Because of the many 
duties that macrophages are involved in, they are able to take on distinct 
phenotypes [16, 17]. The acquisition of a distinct phenotype and activation status 
is highly dependent upon stimulatory factors that are present in the tissue 
microenvironment [18]. Several factors have been shown to alter macrophage 
phenotype and function including arachidonates, complement proteins, 
cytokines, stress hormones, apoptotic cells, catecholamines, and even fatty acids 
[18-24]. Several studies have used a characterization approach whereby gene 
expression profiles following cytokine or microbial stimulation of macrophages 
are used to classify macrophage subsets. From this, two subsets with distinct 
phenotypes have been described: classically activated M1 macrophages and 
alternatively activated M2 macrophages. 
Classically activated macrophages are effector cells that employ pro-
inflammatory and phagocytic functions during anti-microbial and anti-tumoral 
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immune responses. Upon activation by tissue cytokines and chemokines, notably 
IFN-y, TNF-a, and TLR ligands, infiltrating macrophages will induce the activity of 
a combination of transcription factors, including signal transducer and activator of 
transcription (STAT) molecules and NF-kappa B (NF-KB) [25,26]. These 
transcription factors, in turn, up-regulate genes involved in inflammation and 
pathogen clearance, such as reactive oxygen species and nitric oxide [27, 28]. 
Although the pro-inflammatory cytokines that are produced by classically 
activated macrophages are imperative for host defense, they can also cause 
considerable damage to the host. For example, reports have demonstrated that 
macrophage-derived IL-6, IL-23, and IL-1 are associated with the development 
and expansion ofTH17 cells, and the subsequent production of IL-17 has been 
shown to contribute to autoimmune disease, including rheumatoid arthritis and 
inflammatory bowel disease [29-33]. Nonetheless, classical activation of 
macrophages is vital for the protection of the host against viral and microbial 
pathogens, and even tumor development, as long as the response stays tightly 
controlled. 
In contrast, alternatively activated macrophages display anti-inflammatory 
properties and are involved in resolution of the inflammatory response followed 
by wound healing. Alternative activation of macrophages is induced in the 
presence of IL-4 or IL-13, and produce anti-inflammatory cytokines including IL-
10 and TGF-I3, along with increased arginase [34, 35]. Promotion of wound 
healing and tissue repair is induced by the production of various proteases, 
growth factors, and angiogenic factors such as vascular endothelial growth factor 
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(VEGF), matrix metalloproteinases (MMPs), and epidermal growth factor (EGF) 
[36]. 
Macrophage activation, however, is much more complex and can not be 
linearly classified as classically or alternatively activated. Rather than discrete 
stable subpopulations, some scientists believe that macrophages represent a 
spectrum of phenotypes, and there are several documented studies 
demonstrating the flexibility in macrophage programming, with macrophages 
shifting from one functional phenotype to another in response to 
microenvironmental signals [37]. For example, upon clearance of bacteria, 
macrophages will begin to phagocytose apoptotic cells and down-regulate pro-
inflammatory gene transcription in favor of a tissue reparative phenotype [38, 39]. 
This clearly demonstrates phenotypical adaptation rather than substituting 
subsets. 
Macrophages are indeed crucial for tissue homeostasis and host defense, 
but they can also have pathologic roles. For example, macrophages are involved 
in intracellular lipid accumulation and foam cell formation, thus contributing to the 
development and progression of atherosclerosis [40]; macrophage-derived TNF 
and IL-23 mediates the pathology of Crohn's disease [41]; macrophages are key 
regulators in demyelinating disease of the central nervous system, such as 
experimental autoimmune encephalomyelitis (EAE) in mice and multiple sclerosis 
in humans [42]; and they are heavily involved in tumorigenesis [43]. Due to their 
plastic nature and their role in disease pathology, macrophages may make for 
effective therapeutic targets via the manipulation of their functional phenotype. 
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The Role of Macrophages in Cancer 
The association between inflammation and cancer development and 
progression is well established [4, 44, 45]. It is now clear that virtually all tumors 
contain an array of immune cells at densities ranging from subtle inflammation to 
heavy infiltration [46]. Infiltrating immune cells were originally thought to be .. 
involved in the eradication of tumors, and although there is evidence 
demonstrating anti-tumor responses, many of these cells, particularly innate 
immune cells, display tumor-supporting phenotypes. One of the main 
inflammatory components within the microenvironment of primary and secondary 
tumors are macrophages [3]. High density of tumor-infiltrating macrophages 
(TIM) is associated with reduced patient survival in many different forms of 
cancer, including cancer of the breast, prostate, bladder, kidney, endometrium, 
esophagus, as well as follicular lymphoma, and squamous cell carcinoma [47-
51]. This poor prognosis is primarily due to the ability of TIM to produce bioactive 
molecules including growth factors, cytokines, chemokines, and matrix-modifying 
enzymes that promote tumor cell proliferation and growth, survival, angiogenesis, 
activation of epithelial-mesenchymal transition, as well as invasion and 
metastasis [8-1 0, 12, 52]. 
During tumorigenesis, monocytes enter tumors through blood vessels. 
Monocyte and macrophage infiltration can be found in early-stage tumors that 
are beginning to vascularize and late-stage tumors that are invasive and 
metastatic [9, 11, 52]. The constant recruitment of monocytes into tumors can be 
attributed to tumor-derived chemoattractants, including colony-stimulating factor-
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1 (CSF-1), monocyte chemotactic protein-1 (MCP-1), CCl2, CCl3, CCl4, CCl5, 
CCl8, and VEGF [53]. Studies have demonstrated that the expression level of 
these proteins positively correlates with TIM numbers [54]. To further confirm the 
important role of macrophages in cancer progression, early studies were 
conducted using mice with a homozygous CSF-1 null mutation to deplete 
macrophages in a mouse model of breast cancer [55, 56]. Depletion of 
macrophages resulted in reduced progression of pre-invasive lesions to 
malignant lesions, as well as reduced lung metastases. 
Of the many pro-tumoral functions that macrophages exhibit, 
angiogenesis is the most crucial for tumor growth since tumors require the 
development of new blood vessels for expansion [3, 57]. Via the production of 
many essential factors such as Il-1, TNF-a, Il-8, COX-2, MMP-9, and VEGF, 
TIM are able to contribute significantly to angiogenesis [58-64]. Within tumors, 
TIM cluster in areas of hypoxia, which up-regulates the transcription factor 
hypoxia-inducible factor-2a (HIF-2a). HIF-2a activation, in turn, induces the 
expression of VEGF [65]. VEGF expression is also able to up-regulate the 
production of CSF-1, and together, both factors serve as chemoattractants for 
additional macrophage recruitment [66]. Studies have further demonstrated that 
the production of Il-8, Il-1, and TNF-a promotes proliferation and migration of 
endothelial cells, along with matrix remodeling and blood vessel formation 
induced by MMP-9 and VEGF, respectively. 
In addition to angiogenic roles, TIM are also critical mediators in tumor cell 
invasion and metastasis [67, 68]. During the metastatic process, TIM infiltrate the 
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basement membrane where they secrete various MMPs that are able to degrade 
the basement membrane. This allows for the creation of an egress, whereby 
tumor cells can invade into surrounding tissues [8]. Multiphoton intravital imaging 
of the breast microenvironment showed that TIM also directly promote tumor cell 
intravasation into the blood stream [69, 70]. Using this technology, which 
consisted of transgenic mice expressing fluorescently tagged cancer cells, 
endothelial cells, and macrophages, allowed for the visualization of interactions 
between these cell types at the site of intravasation. Wyckoff and colleagues 
found that TIM increased the motility of tumor cells, which was amplified when 
tumor cells were in close proximity with perivascular TIM [69]. In fact, tumor cells 
were found to invade blood vessels only where perivascular TIM were located. 
The use of Csf1oplop PyMT mice, which have reduced macrophage infiltration and 
a decrease in circulating cancer cells, demonstrated the functional importance of 
this interaction for intravasation. Moreover, a macrophage EGF-CSF paracrine 
loop was found to be crucial for intravasation, as inhibition of this signaling 
pathway led to reduced numbers of cancer cells in the blood stream [69]. 
Additional studies demonstrated that TIM also regulate the density of collagen 
fibers, which serve as tram lines for tumor cells and macrophages to travel along 
within the tumor stroma. Many of these fibers are bound to blood vessels, 
resulting in the accumulation of tumor cells at the vessels [71]. 
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The Role of Macrophages in Obesity and Metabolic Diseases 
In addition to having very important roles in the development and 
progression of cancer, macrophages are also heavily involved in obesity-related 
inflammation and metabolic syndrome [5, 72]. In 2003, two studies illustrated that 
in an obese state, macrophages infiltrate the adipose tissue and are primarily 
responsible for the inflammatory environment [6, 7]. Expanding adipocytes and 
neighboring pre-adipocytes produce signals that induce the recruitment and 
accumulation of macrophages into the adipose tissue in both mice and humans. 
During late-stage obesity, adipocyte death serves as an additional mechanism by 
which macrophages infiltrate the adipose tissue [73]. In addition to differences in 
the adipocyte to macrophage ratio, adipose tissue macrophages also display 
functional differences between lean and obese mice [74]. Adipose tissue 
macro phages in lean mice exhibit an anti-inflammatory, alternatively activated-
like phenotype. These macrophages have increased production of IL-10, which 
plays a role in maintaining insulin sensitivity [74, 75]. In contrast, adipose tissue 
macrophages from obese mice have a pro-inflammatory, classically activated-like 
phenotype and they are typically found in 'crown-like' structures around dying 
adipocytes [72, 74]. There are several published stUdies supporting the idea that 
these macrophages are the primary cell type contributing to the pathogenesis of 
obesity-induced diseases, including insulin resistance, type 2 diabetes, and 
atherosclerosis [22, 76-78]. First, there is protection from obesity-induced 
inflammation and insulin resistance in mice lacking CC-chemokine receptor 2 
(CCR2), which is a receptor that is required for the recruitment of inflammatory 
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monocytes and macrophages into tissues [79]. CCR2 and its ligand CCL2 are 
postulated to have a dominant role in the trafficking of monocytes and 
macrophages to the adipose tissue [79,80]. Second, CD11c-DTR mice, which 
are used to selectively deplete CD11c+ classically activated macrophages, also 
show reduced inflammation in the adipose tissue along with improved insulin 
sensitivity [81]. Third, by genetically deleting IKK~ in myeloid cells, Arkan and 
colleagues were able to reduce myeloid cell-mediated inflammation in the 
adipose tissue [82]. Additionally, reconstituting mice with JNK-deficient bone 
marrow conferred similar results [83]. Lastly, ablation of a G protein-coupled 
receptor GPR120, which mediates the anti-inflammatory actions of omega-3 
unsaturated fatty acids, exacerbates inflammation in the adipose tissue and 
insulin resistance [84]. 
It has been suggested that saturated, but not unsaturated, fatty acids 
prompt the activation of M1-like macrophages in the adipose tissue of obese 
mice. This phenomenon is mediated by ligation of TLR-4 and subsequent 
signaling pathways [85-87]. For example, the infusion of lipids adequately 
induces adipose tissue inflammation and insulin resistance in wild-type but not 
TLR-4-deficient mice [88]. Moreover, studies have shown that high fat diet-
induced insulin resistance requires TLR-4 expression by hematopoietic cells in 
the adipose tissue and liver [89, 90]. In addition to TLR-4 studies, others have 
shown that MyD88 signaling may link inflammation and metabolism. Deletion of 
MyD88 in mice confers more severe metabolic disease in response to a high fat 
12 
diet when compared to wild-type mice, suggesting that MyD88 may have a 
protective role [87]. 
Another macrophage-expressing factor that links metabolism and 
inflammation is adipocyte/macrophage fatty acid binding protein (A-FABP). 
Ongoing studies in our lab and others have demonstrated the influence of this 
protein on macrophage inflammatory function under conditions of metabolic 
stress. 
Obesity and Cancer 
Clinical and epidemiological studies have linked obesity and obesity-
associated diseases to increased cancer risk, incidence, and mortality. 
Overweight and obesity led to an almost 2-fold increase in cancer risk in both 
men and women with a body mass index (BMI) of >25 kg/m2 [91]. This increase 
does, however, comply with the type of cancer. For example, in men with a BMI 
of 35-40 kg/m2, there is about a 5-fold increase in hepatocellular carcinoma, 2-3 
fold increase in oesophageal cancer [92], and even the slightest increase in BMI 
can put individuals at risk for cancers of the pancreas, kidney, gastrointestinal 
tract, and liver [93]. In fact, several studies focusing on kidney cancer reported a 
dose-response correlation between increasing weight or BMI and kidney cancer 
incidence [94-96]. Obesity and breast cancer incidence have consistently 
mirrored one another, with a 30-50% increase in breast cancer rates amongst 
obese women, and mortality and survival studies have shown that very obese 
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women, with a BMI of ~40 kg/m2 have a 3-fold increase in breast cancer death 
rates compared to lean women (BMI <20.5 kg/m2) [97]. Cancer of the 
endometrium was the first to be recognized as being associated with obesity. 
Studies show a linear increase in endometrial cancer risk and increasing BMI 
[98, 99]. In regards to prostate cancer, evidence shows that although there is 
only a slightly higher risk of prostate cancer in obese men compared to lean men, 
prostate tumors in obese men are significantly more aggressive and there is a 
higher chance of recurrence after radical prostatectomy [100, 101]. In contrast, 
studies have shown that maintaining healthier weights can actually lower the risk 
for many cancers including colon, breast, endometrium, kidney, and oesophageal 
cancer [99]. In 2009, it was reported that 15-20% of cancer deaths was 
associated with obesity, however in 2010, the American Association for Cancer 
Research annual report showed that 30% of all cancer deaths in the United 
States were associated with obesity. Thus, this relationship is becoming an 
increasing problem, however the mechanism(s) behind the obesity and cancer 
association is poorly understood. 
Currently, the strongest evidence to mechanistically link obesity to cancer 
are hormonal effects. For example, increased estrogen production in the adipose 
tissue of obese women is associated with increased breast cancer risk. This is 
partly due to increased expression and activity of aromatase, an enzyme that is 
responsible for the biosynthesis of estrogen, in both the adipose tissue and 
mammary gland [102]. Additionally, it is well established that obesity leads to the 
development of insulin resistance and chronic hyperinsulinmaemia. Higher levels 
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of circulating insulin leads to a reduction of insulin-like growth factor binding 
protein 1 (IGFBP1), which in turn, increases the availability of insulin-like growth 
factor 1 (IGF1). Insulin and IGF1 both signal through insulin receptors to promote 
cellular proliferation and inhibit apoptosis in many cell types, thus contributing to 
tumorigenesis. Elevated levels in circulating insulin has also been identified as a 
risk factor for many cancers and is associated with late-stage disease and poor 
prognosis [103]. 
Excess adiposity is also associated with an increase in free fatty acids in 
the environment, and numerous studies have looked at fatty acid metabolism as 
a potential mechanism to link obesity to cancer. For example, under obese 
conditions, polyunsaturated fatty acids are chemically oxidized to generate high 
amounts of reactive oxygen species (ROS). ROS, in turn, promote cancer 
development via DNA damage. ROS generated from lipids can also lead to 
cyclooxygenase-2 (COX2) up-regulation, which in turn, promotes colorectal, 
breast, and prostate carcinogenesis [104, 105]. Hyperglycemia and elevated 
triglycerides, which are hallmarks of obesity, can also induce the generation of 
ROS and lead to tumorigenesis [104]. Fatty acid synthase (FAS), which is an 
enzyme that catalyzes fatty acid synthesis, is also associated with poor 
prognosis in breast and prostate cancer patients. 
Park and colleagues showed that obesity is indeed a tumor promoter via 
the administration of a liver chemical carcinogen, diethylnitrosamine (DEN). DEN 
failed to induce hepatocellular carcinoma (HCC) on its own, however HCC did 
develop only in genetic or diet-induced obese mice, and the effect was just as 
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strong as the more common liver tumor promoter, phenobarbital [2]. Moreover, 
they found that the tumor-promoting effects of obesity in HCC were due to the 
low-grade chronic inflammatory state that it promotes, including elevated levels 
of TNF and IL-6 [2, 106]. It is well established that obesity promotes systemic 
low-grade chronic inflammation, but the influence of obesity-induced chronic 
inflammation in cancer development and progression hasn't been well explored. 
Adipose tissue is an organ of many functions that secretes a variety of pro-
inflammatory adipokines and cytokines, including adiponectin, leptin, IL-6, MCP-
1, IL-8, VEGF, and TNF-a, all of which have been implicated in metabolic 
diseases and cancer. Visceral adipose tissue, which has been described as 
being more metabolically active, correlates with circulating levels of leptin, which 
promotes proliferation, angiogenesis, and MMP expression in oesophageal and 
colon cancer [1]. Additionally, TNF-mediated activation of NF-KB has been shown 
to increase nitric oxide (NO) production. NO serves as a substrate for the 
generation of ROS, and ROS in combination with other inflammatory cytokines, 
leads to insulin resistance and glucose intolerance. It has been proposed that 
insulin resistance, ROS, and inflammatory cytokines lead to a vicious cycle since 
these factors facilitate continuous NF-KB activation, and this may be a potential 
hallmark in obesity-induced chronic inflammation and cancer [107]. Because 
macrophages are huge contributors to the inflammatory milieu in both adipose 
tissue and tumors, we decided to focus our work on this cell type in the context of 
obesity and cancer. 
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Fatty Acid Binding Proteins 
Fatty acids are well known for their role in maintenance of cell structure 
and energy metabolism, but they also function as metabolic signaling molecules, 
thus regulating vital cellular and physiological processes. Fatty acids are capable 
of modulating the activity of G protein-coupled receptors (GPCRs) by serving as 
ligands for several GPCRs, including GPR40, GPR43, GPR84, and GPR120. In 
macrophages, GPR120 binds omega 3 fatty acids resulting in anti-inflammation 
and insulin sensitization [108]. Fatty acids can also activate and inhibit kinases, 
such as I kappa kinase ~ (IKK~), and serve as ligands for transcription factors, 
including peroxisome proliferator-activated receptors (PPARs) [109]. In order to 
carry out these tasks, fatty acid binding proteins (FABPs) are required for the 
trafficking and targeting of intracellular fatty acids and other bioactive lipids 
throughout the cell [110]. 
FABPs constitute a family of small (14-15 kDa), highly homologous 
intracellular lipid chaperones that coordinate lipid trafficking to various cellular 
compartments including lipid droplets for storage; the mitochondria for oxidation; 
the nucleus for regulation of gene transcription; and outside of the cell for 
autocrine and paracrine signaling. Most importantly, FABPs are strongly linked to 
the regulation of both metabolic and inflammatory pathways [110, 111]. Thus far, 
nine FABPs have been identified and include adipocyte (A-) , heart (H-), intestinal 
(1-), brain (B-), epidermal (E-), ileal (11-), testis (T-), and myelin (M-) FABPs. 
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However, the nomenclature can be misleading since no FABP is exclusive for a 
given tissue or cell type. In fact, there are tissues and cells that express more 
than one type of FABP. Extensive work has been conducted to elucidate the 
structure and ligand binding characteristics of FABPs. The structural 
characteristics of FABPs consist of I)-barrels arranged in such a way that it forms 
an interior water-filled cavity where the ligand binds. All FABPs reversibly bind 
hydrophobic long chain fatty acids, with the specificity and affinity of ligand 
binding varying amongst the isoforms due to small structural differences. In 
general, FABPs bind saturated long-chain fatty acids with the highest affinity, 
followed by unsaturated fatty acids, and then polyunsaturated fatty acids, as well 
as eicosanoids [112-114].. Tissue distribution of FABP expression varies, ranging 
from fairly widespread, as is the case for H-FABP which has been shown to be 
expressed in a variety of tissues, to narrow, as is the case for A-FABP [110]. 
Generally, FABPs are abundantly expressed in tissues that are actively involved 
in lipid metabolism [115]. For example, FABPs make up 1-5% of all soluble 
cytosolic proteins in adipocytes, hepatocytes, and cardiac myocytes, which all 
undergo high rates of lipolysis. Table 1 summarizes the type and locations of 
FABPs that have been discovered to date. 
Our work focuses on adipocyte/macrophage fatty acid binding protein (A-
FABP) (Gene: FABP4) , also known aP2 [116,117]. It is best-characterized 
member in the FABP family. Initially, A-FABP expression had been thought to be 
restricted to adipocytes, where it is associated with adipocyte differentiation. 
However we, and others, have previously demonstrated that A-FABP is also 
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expressed in macrophages and our lab has shown strong expression of A-FABP 
in dendritic cells. A-FABP expression in macrophages becomes evident upon 
differentiation from monocytes, as well as by treatment with phorbol 12-myristate 
13-acetate, lipopolysaccharide (LPS), peroxisome proliferator-activated receptor 
y (PPAR-y) agonists, insulin, oxidized low-density lipoprotein (ox-LDL), and 
tissue injury [118-121]. In contrast, atorvastatin, a cholesterol-lowering statin, 
reduces A-FABP expression in macrophages in vitro [122]. Treatment of 
macrophages with unsaturated fatty acids also results in A-FABP suppression in 
macrophages. Coleman et aI., conducted a study wherein RAW 264.7 
macrophages were pre-treated with various unsaturated fatty acids followed by 
stimulation with LPS, and despite being stimulated by a highly inflammatory 
factor, these macrophages maintained lower levels of A-FABP when compared 
to control-treated macrophages [123]. 
Macrophage A-FABP binds arachidonic acids and metabolites of the 
cyclooxygenase (COX) and lipoxygenase (LOX) pathways, including compounds 
that act as ligands for PPARs [124]. In fact, several A-FABP ligands have a high 
affinity for PPARs. PPARs are nuclear receptors consisting of three primary 
subtypes, a, ~, and y. PPARs regulate vital cellular processes that impact lipid 
homeostasis, inflammation, reproduction, adipogenesis, wound healing, and 
tumorigenesis. Previous studies from our lab have shown that in macrophages, 
A-FABP prevents cholesterol efflux via the inhibition of the PPAR-y -liver X 
receptor-a (LXR-a) - ATP-binding cassette A 1 (ABCA 1) pathway, and thus 
contributes to macrophage foam cell formation in the context of atherosclerosis 
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[109, 125]. When A-FABP is present, it limits the availability of PPAR-y ligands, 
thus preventing PPAR-y activation and subsequent up-regulation of the genes 
involved in cholesterol efflux, LXR-a and ABCA 1 (Figure 5). Conversely, in A-
FABp-i- macrophages, fatty acids are free to bind to PPAR-y, resulting in LXR-a 
and ABCA 1 expression, and the shuttling of cholesterol out of the cell (Figure 6) 
[109]. In parallel, A-FABP regulates the inflammatory response in macrophages 
(Figures 5 and 6). In A-FABP deficient macrophages, elevated PPAR-y activity 
allows for suppression of NF-KB activity, a mechanism which may be via ligand-
dependent transrepression of NF-KB, although this has yet to be proven. Here, 
PPAR-y undergoes sumoylation in the ligand-binding domain upon activation, 
which targets PPAR-y to nuclear co-repressor (NCoR)/histone deacetylase-3 
(HDAC) complexes on inflammatory gene promoters. Because of this, the 
ubiquityiation/19S proteasome machinery, which indirectly mediates removal of 
co-repressor complexes required for gene transcription, is not recruited. Thus, 
NCoR complexes remain bound to promoters, and inflammatory genes are 
maintained in a repressed state [126]. Additionally, some fatty acids can also 
directly inhibit IKK activity. A-FABP-I- macrophages also display impaired adaptor 
protein 1 (AP1) activity via inhibition of the JNK pathway [110, 127]. Relative to 
wild-type macrophages, A-FABP deficient macrophages show reduced 
expression of several pro-inflammatory mediators in response to LPS and CD40 
ligand stimulation, including prostaglandin E2, iNOS, IL-1a, IL-113, IL-6, IL-12, 
MCP-1/CCL2, and TNFa. However in the presence of A-FABP, restriction of fatty 
acid nuclear localization allows for components of the NF-KB pathway to be 
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activated, which is also a contributing factor to foam cell formation and 
inflammation in atherosclerosis as well as in a model of EAE [109, 126, 128]. 
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Table 1. Family of fatty acid binding proteins. 
Gene Name Alternate Tissue/Ceil Expression 
Names 
Fabp1 Liver FABP L-FABP Liver, intestine, pancreas, kidney, lung. 
stomach 
Fabp2 Intestinal FABP I-FABP Intestine, liver 
Fabp3 Heart FABP H-FABP, MDGI Heart, skeletal muscle, brain, kidney, lung. 
stomach. testis, aorta, adrenal gland, 
mammary gland, placenta . ovary, brown 
adipose tissue 
Fabp4 Adipocyte FABP A-FABP. aP2 Adlpocyte. macrophage. dendritic cell 
Fabp5 Epidermal FABP E-FABP. PA- Skin, tongue, adipocyte. macrophage, 
FABP. mal1 dendritic cell , mammary gland, brain, 
intestine, kidney. liver, lung, heart, skeletal 
muscle, testis . retina, lens, spleen 
Fabp6 Ileal FABP IL-FABP. I- Ileum, ovary. adrenal gland, stomach 
BABP. 
gastrotropin 
Fabp7 Brain FABP B-FABP, MRG Brain, gila cell . retina, mammary gland 
Fabp8 Myelin FABP M-FABP. PMP2 Peripheral nervous system, Schwann cell 
Fabp9 Testis FABP T-FABP TestiS. salivary gland, mammary gland 
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The Relationship Between PPARs and FABP 
A-FABP and PPAR-y share several ligands indicating a functional link 
between the two proteins (Figure 3). Two possible scenarios are 1) FABPs 
target ligands to PPARs, resulting in PPAR activation, or 2) FABPs sequester 
PPAR ligands, resulting in decreased ligand availability and PPAR inactivation. In 
2001, Wolfrum and colleagues sought to understand how signaling molecules 
reached nuclear receptors such as PPARs. Using laser-scanning microscopy, 
they first showed that liver-FABP (L-FABP) and PPAR-a colocalized in the 
nucleus of mouse hepatocytes. Pull-down assays and immunocoprecipitation 
proved that L-FABP and PPAR-a interacted directly, and further transactivation 
assays showed that PPAR a and y transactivation correlated with intracellular L-
FABP concentrations, suggesting that L-FABP transported PPAR ligands to the 
nucleus [129, 130]. Using CV-1 cells transfected with A-FABP, Helledie and 
colleagues demonstrated that A-FABP, when expressed at high levels, resulted 
in negative regulation of PPAR activation and PPAR-mediated gene transcription 
[131]. Our lab previously conducted a study where wild-type and A-FABP-I-
macrophage cell lines were treated with 13-HODE, a high affinity ligand that 
binds both A-FABP and PPARy (Figure 4). Using confocal microscopy, we were 
able to show that in wild-type macrophages, nuclear localization of 13-HODE 
was inhibited, whereas 13-HODE was free to enter the nucleus and bind to 
PPARy in the absence of A-FABP, suggesting that in macrophages, FABPs bind 
and sequester PPAR ligands, acting as negative regulators of PPAR activity. We 
have also demonstrated that in the absence of FABPs, PPAR activity is 
23 
enhanced [109], resulting in the up-regulation of LXRa and ABCA1 expression, 
which leads to enhanced cholesterol efflux and protection from atherosclerosis. 
The finding that A-F ABP deficiency protects against atherosclerosis in the apoE-
deficient murine model complements our data showing that FABPs act to 
sequester PPAR ligands. 
In addition to a model of atherosclerosis, we have also shown that 
elevated PPAR activity due to A-FABP deficiency protects mice from developing 
EAE [128]. In this report, A-FABP deficient mice had lower levels of pro-
inflammatory cytokine expression, including impaired IFN and IL-12 production, 
in the central nervous system tissue compared to wild-type mice, resulting in 
decreased disease incidence and clinical symptoms [128]. This evidence is also 
supported by findings demonstrating that PPAR agonists exert a protective effect 
against EAE development [132]. Moreover, FABPs have high affinity for 
retinoind-binding receptors, including retinoid X receptor (RXR), which is a 
heterodimeric partner of PPARs [133]. Retinoic acid influences macrophage 
inflammatory phenotype by down-regulating IL-12 production via NF-KB inhibition 
[134]. Because A-FABP binds to retinoic acid, it may function as a negative 
regulator of RXRs as well. To complement this, we have shown that A-FABP 
deficient macrophages display elevated responses to agonists of RXR, and 
further published studies have shown that when combined with PPAR agonists, 
RXR agonists confer additional protection from EAE [135]. Thus, our data fit very 
well with literature supporting an anti-inflammatory role of PPARs in metabolic 
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and inflammatory diseases along with the functional link between FABPs and 
nuclear receptors. 
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A-FABP 
Linolenic Acid 
Retinoic Acid 
Linoleic Acid 
Oleic Acid 
15dPGJ2 
Arachadonic Acid 
PPAR-v 
Eicosapentaenoic Acid 
Palmitic Acid 
Stearic Acid 
LTB4 
Prostacyclin 
PGD2 
Figure 3. A-FABP and PPARy ligands. Both A-FABP and PPARy share several 
ligands, thus creating a functional link between these two proteins. 
26 
A 13-HODE OAPt MERGE B 
•• 
.... 
~ 0 .--
~ 
• - .. • 0. ~ 
CO > o. 
c( 0 
LL 
I 
c{ 
Figure 4. A·FABP expression restricts 13·HODE, a PPARy ligand, to the 
cytoplasm. A, 13-HODE (10JjM) (green) was restricted in the cytoplasm of 
macrophages in the presence of A-FABP, but able to enter the nucleus in A-
FABP-I- macrophages (turquoise). B, Quantitation of co-localization of 13-HODE 
in nucleus (**p<O.001). 
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Inflammatory stimuli 
IKK 
~ 
Inflammatory funct ion 
Figure 5. A-FABP promotes inflammation in wild-type macrophages. A-
FABP expression in macrophages limits the availability of PPARy ligands, and in 
doing so, inhibits PPARy activity while allowing components of the NF-KB 
pathway to be activated. 
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Figure 6. A-FABP deficiency promotes an anti-inflammatory response and 
cholesterol efflux. In the absence of A-FABP, fatty acids are free to enter the 
nucleus, bind to and activate PPARy. This results in up-regulation of genes 
involved in cholesterol trafficking, including LXRa, ABCA 1, and CD36. Enhanced 
PPARy activity also inhibits activation of the NF-KB pathway via ligand-
dependent transrepression. Additionally, some fatty acids can directly inhibit IKK 
activity. 
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The Role of A-FABP in Obesity and Other Disease Models 
Despite the extensive work done on the structure and ligand binding 
properties of FABPs, there are still many questions regarding the primary 
functional role of these proteins. The elucidation of A-FABP function was 
facilitated by the production of A-FABP deficient animals generated by Dr. 
Gokhan Hotaslimigil at Harvard University School of Public Health. Mice deficient 
in A-FABP are healthy with no defects in metabolism or reproduction and 
development, however the effects of A-F ABP deletion can be observed when 
mice are subjected to systemic stress such as diet-induced obesity or disease. 
When subjected to genetic or diet-induced obesity, A-FABP deficient mice, 
despite weighing slightly more than wild-type controls, are protected from 
development of insulin resistance and diabetes [124, 136, 137]. Hotamisligil and 
colleagues showed that free fatty acids from a high-fat diet induce the expression 
of TNF-a, a molecule which has been highly connected to obesity-related insulin 
resistance. This study further showed that by binding and shuttling free fatty 
acids to specific intracellular compartments, A-FABP regulates the expression of 
TNF-a. In the A-FABP deficient model, mice failed to express adipose tissue 
TNF-a and showed improved insulin resistance and glucose metabolism 
compared to wild-type mice [136, 137]. 
Numerous observations, including the documented role of PPARy in foam 
cell formation and the ability of PPARy to up-regulate A-FABP expression, 
spurred an examination of the influence of A-FABP deficiency in the development 
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and progression of atherosclerosis. In these studies, A-FABP deficient mice were 
cross-bred with the apoE-deficient background such that the apoE-deficient 
model of atherosclerosis could be exploited. The apoF/-, A-FABP-I- mice 
displayed significant protection from the development of atherosclerosis when 
compared to apoE-1-, A-FABP+I+ animals. Moreover, apoE-1-, A-FABP-I- mice fed a 
normal diet developed 88% less atherosclerosis while apoF/-, A-FABP-I- mice fed 
a high fat, Western diet developed 91 % less atherosclerosis when compared to 
apoE-1-, A-FABP+I+ mice fed either diet, suggesting that A-FABP provides an 
increased protective effect under conditions of metabolic excess. Further bone 
marrow transplantation studies where A-FABP-I-, ApoF/- bone marrow was 
transplanted into A-FABP+I+,ApoE-1- revealed that the atheroprotective effect of A-
FABP deficiency was primarily due to its expression in macrophages [138]. 
The fact that mice under normal physiologic conditions do not have a 
compromised phenotype when A-FABP is deleted, but they benefit when faced 
with systemic inflammatory or metabolic stress, gives rise to the question of why 
A-FABP exists if it seems to promote dysfunction. Acutely activated signaling 
systems, such as in acute inflammation, display regulatory mechanisms to 
amplify and/or attenuate a particular response. A-FABP seems to be required to 
induce a strong inflammatory response. However too strong of a response can 
be damaging. In an obese state, macrophages are constantly exposed to excess 
free fatty acids and pro-inflammatory cytokines released from adipocytes. This 
may result in an increased and continuous expression of A-FABP in 
macrophages, leading to a sustained polarized pro-inflammatory phenotype and 
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systemic low-grade chronic inflammation. This scenario has been demonstrated 
in the promotion and progression of atherosclerosis, but could this also be the 
case in cancer? 
Hypothesis and Significance 
Published studies have suggested a link between FABP expression and 
cancer progression, but the focus has been on FABP expression in cancer cells 
themselves as opposed to primary cells of the host, and the results are quite 
mixed. For example, reduced levels of L-FABP, I-FABP, and A-FABP are 
associated with the progression of liver, colon, and bladder cancers [139-141], 
whereas increased levels of B-FABP and E-FABP have been found in the 
advancement of astrocytoma tumors and prostate cancer, respectively [142, 
143]. Neiman and colleagues demonstrated that A-FABP expression in 
adipocytes promoted ovarian cancer cell metastasis to the omentum, an organ 
primarily composed of adipocytes, while A-FABP deficiency led to a significant 
reduction in metastatic tumor growth in mice [144]. However, many tumors 
display heavy immune cell infiltration, and the role of FABP expression in 
leukocytes in the regulation of tumor growth and progression has not been 
explored. 
Furthermore, A-FABP expression levels in macrophages is up-regulated in 
response to a high fat diet, particularly saturated fatty acids found in a Western 
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diet, and contribute to a polarized pro-inflammatory phenotype in macrophages 
as well as the development and progression of a cluster of diseases that make 
up metabolic syndrome. One study conducted by Hancke et aI., focused on A-
FABP expression in the serum of breast cancer patients, and the results showed 
higher A-FABP levels in breast cancer patients compared to healthy patients, 
and this expression was increased even further in obese breast cancer patients 
[145]. Additionally, the A-FABP expression was found to be associated with 
increased breast cancer risk and positively correlated with tumor size and lymph 
node involvement [145], suggesting that A-FABP not only has a putative role in 
cancer progression, but may also exacerbate this disease under obese 
conditions. 
Over the past few years, studies in our lab have focused on macrophage 
plasticity and how this can be used in the treatment of a variety of diseases. Our 
work has provided evidence that macrophages possess a spectrum of activation 
states rather than existing as distinct subsets. In response to changes in the 
microenvironment, macrophages can reversibly shift their phenotype through a 
multitude of patterns. For example, by treating macrophages with different 
cytokines, distinct functional phenotypes can be observed, and sequentially 
treating macrophages with multiple cytokines results in a succession through 
several functional phenotypes [18]. This can also be seen in vivo whereby 
distinct macrophage phenotypes that are established in aged or tumor-bearing 
mice can be altered by inducing changes in the microenvironment [24, 37]. As 
mentioned previously, A-FABP mediates both metabolic and inflammatory 
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pathways, thus regulating the outcome of innate and adaptive immune responses 
and making A-FABP a potential therapeutic target for several inflammatory and 
metabolic diseases, as well as cancer [110]. Moreover, it has been reported that 
a genetic polymorphism in the A-FABP locus in humans [146], which results in 
reduced A-FABP expression, produces a similar phenotype as in mice, 
suggesting that the biological roles of A-FABP are similar between species and 
inhibiting this protein in humans is feasible. The identification of small molecule 
inhibitors of A-FABP suggests that targeting this protein for therapeutic purposes 
is attainable, however this also requires a more in-depth understanding of how A-
FABP functions on both a cellular and whole animal level. Herein, we address a 
more complete understanding of how A-FABP regulates cancer progression. 
Given our previous findings regarding the role of A-FABP in macrophage 
inflammatory function, we hypothesize that macrophage expression of A-FABP 
may influence the functional outcome of tumor-macrophage interactions in the 
tumor microenvironment. Moreover, because a high fat diet induces A-FABP 
expression in macrophages, we also hypothesize that A-FABP may serve as a 
link between high fat consumption and cancer progression. 
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MATERIALS AND METHODS 
Mice and macrophage cell lines. 
A-FABP-I- mice were generated as previously described [137, 147], and back-
crossed >10 generations onto a C57BU6J background. A-FABP-I- mice are bred 
and maintained at the University of Louisville Research Resources Facility. All 
animal care and experimental procedures used in this study were approved by 
the University of Louisville'S Institutional Animal Care and Use Committee. A-
FABP-I- macrophage cell lines used in this study were generated by J2 retroviral 
transformation of bone marrow progenitors as previously described (CITATION). 
Normal and High Fat Diet 
High fat diet (60% kcal from fat) food and its matched low fat diet control (10% 
kcal from fat) was purchased from Research Diets, Inc. After being weaned, WT 
and A-FABP-I- mice were placed on either diet for 120 days. Tumor studies were 
then performed. The formula of both the normal and high fat diet is below. 
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Table 2. Formula of Normal Diet 
Formula Normal (10%) Diet 
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Table 3. Formula of High Fat Diet 
Form ula High Fat (60%) Diet 
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Tumor models. 
LU2 Lewis Lung Carcinoma cells were obtained from the late Dr. Gordon Ross of 
the James Graham Brown Cancer Center in Louisville, KY. Tumors were 
maintained by in vivo passage with limited intermittent culture in vitro. Tumor 
cells were injected subcutaneously into the left flank of wild-type C57BU6J 
(Jackson Laboratories), A-FABP+I-, or A-FABP-I- mice. Five to seven mice were 
used in each group (10% wr, 10% A-FABP-I-, 60% wr, 60% A-FABP-I-) during in 
vivo studies and an in vitro tumor invasion study. Tumors were measured at 3-
day intervals with calipers at two bisecting diameters and an approximate volume 
was calculated by the formula {(OA) x (large diameter) x (small diameter)2}. Mice 
were sacrificed after 26 days. To prepare single cell suspensions, resected 
tumors were digested in a digestion mixture consisting of 5% FBS in RPMI 1640, 
0.5mg/ml collagenase A (Roche Diagnostic), 0.2mg/ml hyaluronidase type V 
(Sigma-Aldrich), and 0.02mg/ml DNase I (Sigma-Aldrich) at 37°C for 30 minutes 
on a rotating platform. The resulting cell suspensions were filtered through 70l-lm 
cell strainers (BD Biosciences) and washed with 5% FBS in RMPI 1640. Cell 
debris/dead cells were removed by centrifugation with Lymphocyte-M (Cedarlane 
Laboratories) as recommended by the manufacturer. Tumor-infiltrating 
macrophages were purified by positive selection with anti-CD11b (Mac-1) 
magnetic beads (Miltenyi Biotec). A purity of >95% CD 11 b + cells was confirmed 
by flow cytometry. 
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Generation of bone marrow-derived macro phages. 
Bone marrow-derived macro phages were generated from wild-type and A-FABP-
/- mice. Briefly, femurs and tibias from 8-10 week old mice were flushed with 
DPBS and bone marrow was filtered and washed. Bone marrow was plated 
overnight in RPMI 1640 supplemented with 10ng/ml M-CSF (R&D Systems). 
After overnight incubation, non-adherent cells were plated in RPMI 1640 
containing 25% filtered L929 fibroblast supernatants (ATCC) and 10ng/ml M-CSF 
in 6-well ultra low cluster plates (Corning). Cells were harvested on day 7 and 
purified by centrifugation on 35% Ficoll (Atlanta Biologicals). Macrophages were 
analyzed for CD11c, CD11 b, CD80, CD86, CD40, and I-Ab expression by flow 
cytometry. Macrophages were consistently >98% CD11 b+. 
Flow Cytometric Analysis. 
For cell composition of tumor, 106 single cells were treated with Fc block (BD 
Biosciences) for 15 minutes prior to incubation with fluorochrome-conjugated 
anti-CD4, anti-CD8, anti-CD19, anti-CD11 c, anti-CD11 b, anti-F4/80, anti-NK1.1, 
and anti-Ly6G (all from BD Biosciences) for 30 minutes at 4°C. Samples were 
analyzed using a FACS Calibur flow cytometer and FlowJo Software (Tree Star 
Inc.). 
Quantitative Real-time RT -PCR analysis. mRNA was isolated from 106 purified 
tumor-infiltrating macrophages and converted to cDNA using MACS One-Step 
cDNA Columns (Miltenyi Biotec). Real-time RT-PCR was performed with a DNA-
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Opticon 3 Monitor (Bio-Rad) using SYBR Green (Qiagen). MIF, MCP-1, CSF-1, 
VEGF, EGF, MMP-12, MMP-9, TNFa, TGFj3, Il-6, Il-10, Il-12, Il-15, Il-23, 
FABP4, and j3-actin expression was analyzed by Quantitect Primer Assays 
(Qiagen). Results were normalized to j3-actin. Relative expression of RNA 
transcripts were quantified using the Relative Expression Software Tool, REST. 
Western blot analysis. 
106 macrophages were lysed in buffer containing 25mM Tris-HCI, 1 % 
deoxycholate, 0.35M NaCI, phosphatase inhibitor solution (Cayman Chemical), 
and 1 % Triton X-100 (Fisher Scientific). Protein quantity was assayed by 
bicinchoninic acid (Pierce) and 12IJg of protein was loaded per well on a 10% or 
15% Tris-HCI gel (Bio-Rad). The contents of the gel were transferred onto 
nitrocellulose membranes (Amersham Biosciences) using a Trans-Blot SemiDry 
Transfer Cell (Bio-Rad). The membranes incubated with different antibodies. 
Antibody-bound proteins were detected using an ECl Western Blotting Analysis 
System (Amersham Biosciences), and the membranes were exposed to Kodak 
Biomax Xl X-ray Film (Eastman Kodak). 
Immunohistochemistry. 
Tumors were excised and snap frozen in tissue freezing medium (OCT). Tissue 
blocks were cut and fixed with cold acetone. To detect intratumoral MMP-9 
expression or tumor vascularization, the sections were first blocked with 2.5% 
BSA in 10X PBS, and then stained with biotinylated anti-MMP-9, anti-CD31 (R&D 
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Systems), or anti-MMP-12 (Santa Cruz) for 1 hour at room temperature. After 
washing, the sections were incubated with VECTASTAIN Elite ABC Reagent 
(Vector Laboratories) for 30 minutes. Sections were developed with peroxidase 
substrate solution DAB to desired stain intensity and counterstained with 
hematoxylin to provide morphologic detail. The images were taken and analyzed 
with Aperio Imagescope Software (Aperio Technologies). 
Tumor Invasion Assay 
CD11 b+ TIMs were isolated from WT and A-FABP-/- mice on a normal or high fat 
diet. 1x10"6 TIMs were seeded into the bottom chamber of the Fluoroblok Tumor 
Invasion System (BD Biosciences) in serum-free media. Serum-free media and 
media alone were used as negative and positive controls, respectively. 2.5x10"4 
LLl2 cells were seeded in the top chamber in serum-free media. Tumor cells 
were allowed to invade through the 0.81Jm Matrigel matrix for 20 hours at 37°C. 
Invaded tumor cells were then stained with calcien for 1 hour at 37°C. 
Fluorescence of invaded tumor cells was read at 494/517nm (Ex/Em) using a 
fluorescent plate reader (SoftMax Pro). Pictures of the fluorescent invaded tumor 
cells were taken with a fluorescent microscope (Evos). Magnification 20X. 
Oil Red 0 Staining 
Tumors were excised and snap frozen in tissue freezing medium (OCT). Tissue 
blocks were cut and fixed with 10% neutral buffered formalin for 10 minutes and 
then with propylene glycol for 2 minutes. To look at adipocyte infiltration, tumors 
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were stained with filtered Oil Red 0 0.05% in propylene glycol (Poly Scientific) for 
1 hour. After washing in distilled water, tumors were counterstained with Mayer's 
Modified Hematoxylin (Poly Scientific) for 30 seconds. Tumor stainings were 
preserved with Faramount Aqueous Mounting Medium (OAKO). 
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RESULTS 
The Role of A-FABP in Tumor Growth and Metastasis 
The tumor microenvironment enhances A-FABP expression in 
macrophages. 
To determine the expression level of A-FABP in macrophages in response 
to tumor burden or the tumor microenvironment, WT mice were challenged with a 
subcutaneous injection of Lewis Lung Carcinoma (LLl2) cells, and after 26 days, 
CD11 b+ macrophages were isolated from the spleen. WT mice without tumors 
were used as a control. RT-PCR analysis showed that splenic macrophages 
isolated from tumor-bearing mice had about a 20-fold increase in A-FABP mRNA 
levels compared to splenic macrophages taken from mice without a tumor 
(Figure 7A). Additionally, bone marrow-derived macrophages generated from 
WT mice were treated with LLl2 supernatant or media alone. These results also 
showed a significant increase in A-FABP mRNA levels in macrophages exposed 
to tumor supernatant (Figure 7B) when compared to unstimulated macrophages, 
suggesting that the tumor microenvironment is sufficient to induce A-FABP 
expression in macrophages. 
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A-FABP deficiency suppresses metastasis, but not tumor growth. 
To elucidate the function of A-FABP in tumor growth and metastasis, mice with 
different levels of A-FABP expression were used (A-FABP+I+, A-FABP+I-, and A-
FABP-I-). Tumors grew at a similar rate between these groups of mice, and there 
was no difference in the tumor weight (Figure 8). However, there was a 
significant difference in metastasis, with WT mice averaging about 15 metastatic 
nodules in the liver and about 8 nodules in the lung, while little to no spots of 
metastasis were observed in A-FABP-I- mice (Figure 8). A-FABP+I- mice showed 
about a 50% reduction in metastatic nodules in both liver and lung as compared 
to WT mice (Figure 8). Taken together, this data shows that A-FABP deficiency 
protects mice from metastasis even at the same tumor growth rate. 
A-FABP deficiency reduces the production of pro-inflammatory and 
metastasis-promoting proteins in tumor-infiltrating macrophages. 
Metastasis is a multi-step process that involves proteins of the extracellular 
matrix, cytokines, chemokines, and growth factors. Many of these factors, 
including MMPs, EGF, CSF-1, and MCP-1, are secreted by tumor-infiltrating 
macrophages (TIMs), and are critical for in the induction of metastasis. To further 
confirm the role of A-FABP in metastasis, we observed the expression levels of 
various molecules involved in the metastatic process in CD11 b+ TIMs isolated 
from WT and A-FABP-I- mice. As shown in Figure 9, TIMs isolated from A-FABP-
1- mice had a 30-fold decrease in MMP-9 expression, 20-fold decrease in MMP-
12 expression, and about a 10-fold decrease in MCP-1, CSF-1, and EGF 
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expression as compared to TIMs isolated from WT mice. Moreover, compared to 
WT TIMs, A-FABP-I- TIMs showed reduced expression of TNF-a, IL-6, and IL-23, 
while exhibiting higher levels of anti-inflammatory proteins, TGF-p and IL-10 
(Figure 98). Bone marrow-derived macrophages form WT and A-FABP-I- mice 
also exhibited similar gene expression levels after stimulation with LLl2 
supernatant in vitro (data not shown). Additionally, staining of frozen tumor 
sections confirmed more MMP-9 and MMP-12 production in the tumor tissue 
from WT mice than that of A-FABP-I- mice (Figure 9C, 80). However, when 
tumor sections were stained with CD31 to observe blood vessel formation in LLl2 
tumors, there were no statistical differences between WT and A-FABP-I- mice 
(data not shown). 
Use of a small molecule inhibitor of A-FA8P also suppresses metastasis. 
To further evaluate the function of A-FABP in suppressing metastasis, we 
employed a small molecule inhibitor of A-FABP, HTS01037 [148]. Oral feeding of 
HTS01037 did not affect tumor growth (Figure 108), but it did suppress tumor 
metastasis to the lung (Figure 10C, 100). Some inhibitor-treated mice exhibited 
similar numbers of metastatic nodules as compared to non-treated mice, but the 
size and intensity of the nodules were much less than control groups (Figure 
10C, 100). More importantly, TIMs isolated from inhibitor-treated mice showed a 
significant decrease in MMP-9 and MMP-12 gene expression levels compared to 
control mice (Figure 10E). When HTS01037 was added to in vitro cultured bone 
marrow-derived macrophages pre-stimulated with LLl2 supernatant, MMP-9 and 
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MMP-12 production was also reduced in a dose-dependent manner (Figure 
10A). These data further demonstrate that A-FABP suppresses metastasis via 
impacting the production of metastasis-promoting proteins by TIMs. 
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Figure 7. Increased A-FABP expression in macrophages in response to the 
tumor microenvironment. A, Splenic macrophages isolated from tumor-bearing 
mice have increased mRNA levels of A-FABP when compared to splenic 
macro phages isolated from mice without a tumor. B, bone marrow-derived 
macrophages treated with tumor supernatant show higher mRNA levels of A-
FABP compared to the untreated group (* p = 0.001). 
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Figure 8. A .. FABP deficiency suppresses tumor metastasis. Compared to A-
FABP+I+ mice, A·FABP heterozygous knockouts showed about a 50% reduction 
in lung and liver metastasis, which was reduced even further in A-FABP 
homozygous knockouts. A is graphical representation of B. (Conducted by Bing 
Li). 
48 
B 
MIF rr-
ceLl ,...-
C F . l r,- -
V GF ~ 
£GF ~ . 
_ WT 
;. . ;. P • 
MMP-17 ~---
"MP -
o l' 20 )0 ~o 
Relative mR A levelr.ln TlMs 
rNF~ ill-l~-
TGF~ ======;}~ 
IL·10 --
IL·U --
IL·15 -
IL·2J ""--
o t ,~s, 
Rolatlve mRNA' IIols ,n TIMs 
o 
.FAa;.;. = 0-
o o. a 02 0 t~ t o. 
MMp·, po Ii • lolel c;oll, WT . __ _ 
A·FA8P ·I· 
.00 60: 0 ~ 0 
MP-12 posllve 10le' ulls 
Figure 9. A-FABP deficient macrophages show decreased production of 
pro-inflammatory and metastasis-promoting proteins. A, RT -PCR analysis of 
TIM isolated from wr and A-FABp.f· mice. Compared to wr mice, A_FABpot• 
show reduced expression of proteins involved in metastasis, including MMP-9, 
MMP-12, EGF, and CCL2; along with reduced expression of pro-inflammatory 
cytokines such as TNF-a and IL-6, and increased of expression of anti-
inflammatory cytokines TGF-J3 and IL-10. Band C, Immunohistochemical 
analysis shows reduced expression of MMP-9 and MMP-12 in the tumor tissue of 
A_FABpot• mice compared to that of wr mice (* p = 0.001) (Conducted by Bing 
U). 
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Figure 10. HTS01037, a small molecule inhibitor of A-FABP, reduces lung 
metastasis and MMP production, but has no effect on tumor growth. A, 
Bone marrow-derived macrophages from wr mice were treated with increasing 
concentrations of HTS01037. RT-PCR analysis shows that MMP-9 and MMP-12 
mRNA levels decrease as the concentration of the inhibitor increases. B through 
E, wr mice were treated with HTS01037 or vehicle. B, Inhibition of A-FABP had 
no effect on tumor growth, however there was reduced lung metastasis in 
inhibitor-treated mice as compared to the control group (C, D). E, TIMs isolated 
from inhibitor-treated mice had reduced MMP-9 and MMP-12 production 
(Conducted by Bind Li). 
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The Role of A-FABP in Tumor Growth and Metastasis in Diet-Induced 
Obese Mice 
A-FABP is not only increased in response to the tumor microenvironment, 
but it is also increased in response to high fat consumption. 
Previous studies have demonstrated higher macrophage A-FABP levels in diet-
induced obese mice compared to lean mice, as well increased expression in 
atherosclerotic lesions of obese mice compared to lean or healthy mice [137]. 
We have already shown significantly higher levels of A-FABP in splenic 
macrophages in response to the tumor microenvironment, but is this expression 
increased even more in obese tumor-bearing mice? Here, WT mice were fed a 
normal (10%) diet or high fat (60%) diet for 120 days prior to implantation of LLl2 
cells. Figure 11 shows that WT and A-FABP-I- mice fed a high fat diet have 
similar weights. CD11 b+ splenic macrophages and TIM taken from high fat-fed 
WT mice showed a significant increase in A-FABP expression when compared to 
splenic macrophages and TIMs isolated from mice fed a normal diet, respectively 
(Figure 12). These data along with results from Figure 7 suggest that A-FABP 
expression level increases in response to both the tumor microenvironment and 
high fat consumption in macrophages. 
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A-FABP deficiency confers protection against tumor growth and 
metastasis in both lean and diet-induced obese mice. 
Next, we observed the effect of A-FABP deficiency on tumor growth and 
metastasis under conditions of high fat feeding. There was no difference in tumor 
growth between WT and A-FABP-I- mice fed a regular chow diet. There was also 
no observed difference in tumor growth in WT mice treated with an inhibitor of A-
FABP when compared to the untreated group (Figure 10). This same trend was 
also observed in WT and A-FABP-I- mice fed a normal (10%) diet, however when 
mice were placed on a high fat (60%) diet, WT mice showed a significant 
increase in tumor growth, while A-FABP-I- mice fed a high fat diet displayed 
reduced tumor growth rates that were similar to those of lean mice (Figure 13A). 
The tumor weights correlated with tumor growth rates between each group of 
mice (Figure 13B). 
We also observed lung metastasis in normal (10%) and high fat (60%) diet 
fed WT and A-FABP-I- mice. WT mice on a normal diet averaged about 7 
metastatic nodules, while WT mice on a high fat diet averaged about 12 
metastatic nodules in the lung. A-FABP-I- mice on normal or high fat diets showed 
a significant reduction in lung metastasis with an average of 2 and 4 metastatic 
nodules in the lung, respectively (Figure 14). To further determine the role of A-
FABP in high fat consumption and metastasis, we assessed TIM-mediated tumor 
cell invasion using an in vitro tumor invasion assay. CD11b+ TIM isolated from 
WT and A-FABP-I- mice on normal and high fat diets were seeded in the bottom 
chamber of the invasion system with LLl2 cells seeded in the top insert of the 
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invasion system. Tumor cells were allowed to invade the Matrigel matrix for 20 
hours. As shown in Figure 15, TIMs isolated from high fat fed WT mice induced 
the highest level of tumor cell invasion, followed by TIM from normal diet fed 
mice. TIMs taken from A-FABP-I- mice fed either diet showed a reduction in the 
ability to induce tumor cell invasion. These data are also consistent with the in 
vivo lung metastasis data (Figure 15). 
Tumors from high fat fed WT mice show an increase in macrophage 
infiltration. 
To determine the immune cell composition of WT and A-FABP-I- tumors, 
single cell suspensions were generated and used in flow cytometric analysis. 
Compared to tumors from normal diet fed WT mice, there was no significant 
difference in CDS+ T cell, B cell, or NK cell infiltrates in each group of mice 
(Figure 16 C-E). However, there was significant increase in macrophage 
infiltration in tumors from high fat fed WT mice (Figure 16A) along with an 
increase in CD4+ T cells (Figure 16B). Surprisingly, there was also a significant 
increase in CD4+ T cells in high fat fed A-FABP-I- mice (Figure 16B). Whether 
these CD4+ cells found in high fat fed WT and A-FABP-I- tumors were 
CD25+Foxp3+ or CD25+Foxp3- was not determined. 
A-FABP deficiency, despite a normal or high fat diet, decreases the 
production of pro-inflammatory cytokines and proteins involved in 
metastasis. 
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Next we determined the cytokine profile of TIM isolated from WT and A-
FABP-I- mice fed a high fat diet. Relative to TIM isolated from normal diet fed WT 
mice, TIM from high fat fed WT mice showed an increase in several proteins 
involved in metastasis, including MIF, VEGF, and MMP-9, which may explain 
why more metastatic nodules were observed in these mice. Conversely, TIM 
taken from A-FABP-I- mice fed a high fat diet showed a reduction in metastasis-
promoting proteins and pro-inflammatory cytokines, while increased mRNA levels 
of anti-inflammatory cytokines, TGF-13 and IL-10 (Figure 17). These data are in 
conjunction with the cytokine profile shown in Figure 9, suggesting that A-FABP 
deficiency can promote an anti-tumoral phenotype in macrophages despite 
dietary conditions. In the diet-induced obese models, there was a drastic 
increase in CCL2 mRNA levels. This chemokine has been implicated in the 
recruitment of macrophages to the adipose tissue in obese mice and humans [7]. 
Compared to WT mice on a normal diet, TIM isolated from high fat fed WT mice 
had about a 7000-fold increase in CCL2 followed by a 2000-fold increase in TIM 
from high fat-fed A-FABP-I- (Figure 178). These data suggest that despite the 
increase in CCL2 levels, which seems to correlate with increased macrophage 
recruitment in tumors of high fat fed mice (will be discussed later in Figure 16), A-
FABP-I- TIM still display an anti-tumoral phenotype, indicating that it is the 
activation state rather than quantity that influences the LU2 tumor outcome. 
We also looked at the expression of the metastasis-promoting protein, 
MMP-9, in the tumor tissue as well as TIM by Western blot (Figure 19 and 18, 
respectively). When compared to normal diet or high fat diet fed WT mice, A-
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FABP-I- mice showed reduced MMP expression on either diet. Moreover, CD31, 
an endothelial cell marker, was also observed in the tumor tissue. Although there 
was no difference in the expression in normal diet fed WT and A-FABP-I- mice 
(data not shown), there was a significant reduction in CD31 expression in A-
FABP-I- mice on a high fat diet relative to high fat fed WT mice (Figure 19). Using 
an Oil Red 0 stain, we were able to look at lipid deposition in the tumor. As 
expected, it appears to be lipid deposits in the tumors of high fat fed WT and A-
FABP-I- mice compared to normal diet fed mice (Figure 20). However, the role of 
these cells in our model has not been explored. 
Several studies have demonstrated the requirement of NF-KB activation in 
macrophages for cancer progression [149, 150]. NF-KB activation in 
macrophages has been shown to trigger the release of a variety of cytokines 
including TNF-a and IL-6, which induce pro-survival signals in tumor cells. 
Additionally, these macrophages also release metastasis-promoting proteins 
including VEGF and CSF-1, which support malignant progression and tumor 
growth. Here, we evaluated the activation status of NF-KB in TIM. Compared to 
TIM isolated from high fat fed WT mice, A-FABP-I- on the same diet displayed a 
drastic reduction in the phosphorylation of the p65 subunit of NF-KB (Figure 21). 
These data complement those in Figure 17, as this may be why there is reduced 
expression of metastasis-promoting proteins and pro-inflammatory cytokines in 
TIM from A-FABP-I- mice. 
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• Before Tumor Implantation 
D After Tumor Implantation 
Figure 11. Weight of WT and A-FABP-I- mice fed a normal or high fat diet. 
Weight of WT and A-FABP-I- mice fed a normal or high fat diet was taken before 
and after tumor implantation. High fat fed A-FABP-I- mice have weights that are 
similar to WT mice on the same diet. 
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Figure 12. A-FABP expression in lean versus diet-induced obese mice. 
Splenic macro phages (A) and TIM (B) isolated from high fat fed WT mice show 
higher mRNA levels of A-FABP compared to lean counterparts (* p = 0.001). 
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Figure 13. A-FABP deficiency protects against tumor growth in mice fed a 
high fat diet. High fat fed wild-type mice had a significant increase in tumor 
growth (A) and weight (B), whereas A-FABP-I- mice on the same diet had tumor 
growth rates and weight that were very similar to that of lean mice. 
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Figure 14. Lung metastasis in WT and A-FABP-'- mice fed a normal or high 
fat diet. Relative to normal diet fed WT mice, high fat fed WT mice showed a 
significant increase in metastasis to the lung, which can reduced in A-FABP 
deficient mice fed either diet. 
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Figure 15. TIM-induced invasion of LU2 cells. A, an in vitro tumor invasion 
assay was performed by seeding TIM from wr and A-FABP-I- mice on a normal 
or high fat diet in the bottom chamber of the invasion system and LU2 tumor 
cells in the top chamber. Tumor cells were allowed to invade a Matrigel matrix for 
20 hours. Tumor cells that did invade were stained with a fluorescent dye, 
calcien. B, quantification of calcien-stained tumor cells that invaded through the 
Matrigel matrix mediated by tumor-infiltrating macrophages. 
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Figure 15. C, Fluorescent microscopy images of LU2 tumor cells that invaded 
through the Matrigel matrix mediated by tumor-infiltrating macrophages. 
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Figure 16. Composition of immune cell infiltration in tumors from WT and 
A-FABP-I- mice on a normal or high fat diet. Single cell suspensions of tumors 
from WT and A-FABP-I- mice fed a normal or high fat diet were used to elucidate 
the composition of the immune cell infiltrate by flow cytometry. There was no 
significant difference in CDS+ T cell , B cell , and NK cell infiltrates between each 
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group of mice, however, there was a significant increase inCD4+ T cells in tumors 
from high fat fed WT and A-FABP-I- mice, as well as F4/80+CD11b+ macrophages 
from high fat fed WT mice relative to tumors from normal diet fed WT mice. 
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Figure 17. TIM from normal and high fat diet fed A-FABP deficient mice 
show decreased production of pro-inflammatory and metastasis-promoting 
proteins. RT-PCR analysis of TIM isolated from wr and A-FABP-I- mice fed a 
normal or high fat diet. A, compared to normal diet fed wr mice, TIM isolated 
from A-FABP-I- mice show reduced expression of proteins involved in metastasis 
and pro-inflammatory cytokines while displaying increased of expression of anti-
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inflammatory cytokines TGF-(3 and IL-10. In contrast, TIM from high fat fed wr 
mice display increased mRNA levels of MMP-9, VEGF, and MIF (*p = 0.001). B, 
moreover, compared to TIM from normal diet fed wr mice, TIM from both high 
fat fed wr and A-FABP-I- mice show a dramatic increase in CCL2 expression (* p 
= 0.001). 
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Figure 18. Decreased protein expression of MMP-9 in TIM from A-FABP-I-
mice. Protein Iysates taken from wr and A-FABP-I- mice fed a normal (A) or high 
fat diet (8) were used to examine at MMP-9 expression by Western blot. 
Compared to wr TIM, TIM isolated from A-FABP-/- mice display reduced protein 
expression of MMP-9. 
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Figure 19. Immunohistochemical staining in WT and A-FABP-l- tumors. A, 
MMP-9 expression in tumor tissue. Compared to wr on a normal of high fat diet, 
A-FABP-I- tumors showed a significant reduction of in MMP-9 expression on 
either diet. B, CD31 expression in tumor tissue. Tumors from high fat fed A-
FABP-I- mice showed reduced CD31 expression and vascularization than tumor 
from wr mice. 
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Figure 20. Lipid deposition in WT and A-FABP-I- tumors from normal and 
high fat diet fed mice. Using an Oil Red 0 stain, lipid deposition was observed 
in the tumors displaying a more intense stain in tumors from high fat fed WT and 
A-F ASp-l- mice when compared to mice fed a normal diet. 
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Figure 21. NF-KB activation in TIM taken from WT and A-FABP-I- fed a high 
fat diet. Protein Iysates taken from WT and A-FABP-I- mice fed a high fat diet 
were used to look at NF-KB expression by Western blot TIM isolated from diet-
induced obese A-FABP-I- mice show significant phosphorylation of p65 when 
compared to TIM from WT mice. 
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DISCUSSION 
The obesity epidemic in the United States is steadily increasing. Currently, 
about two thirds of the adult population in the U.S. is considered to be obese 
[151], and parallel to this are increasing rates of obesity-related cancer deaths 
[93]. These statistics demonstrate the urgent need to understand the 
mechanisms of obesity-associated cancer progression. In the current study, we 
identify a factor that appears to serve as a link between high fat consumption and 
cancer progression, A-FABP. 
Herein, we demonstrate a contribution of host A-FABP expression towards 
tumor metastasis and present evidence that A-FABP expression in macrophages 
facilitates the acquisition of tumor-promoting functions induced via macrophage-
tumor interactions. Moreover, our findings suggest that under conditions of high 
fat feeding, A-FABP exacerbates the acquired tumor-promoting functions of 
macrophages. In the normal (10%) diet LLl2 model, tumor metastasis was 
consistently lower in A-FABP-I- mice despite equivalent tumor growth kinetics, 
indicating that the effect on metastasis was unrelated to tumor burden. However, 
in the high fat (60%) diet model, lower metastasis appeared to be related to 
reduced tumor load and vascularization, suggesting that A-FABP deficiency may 
have an enhanced protective effect in diet-induced obese mice. 
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Since the expression of A-FABP is largely limited to adipocytes and 
mature myeloid cells, including macrophages and dendritic cells, we focused the 
study on macrophages as likely contributors to the observed phenomenon. We 
found that TIM isolated from both normal and high fat diet fed A-FABP-I- mice 
displayed reduced expression levels of proteins involved in inflammation and 
metastasis while up-regulating genes that are anti-inflammatory. Many studies 
suggest that the tumor-supporting functions of macrophages are due to an 
alternatively activated, M2-like phenotype. It is this phenotype that promotes 
cancer progression via remodeling of the extracellular matrix and angiogenesis 
[152, 153]. In our normal and high fat diet LLl2 model, A-FABP-I- TIM did display 
up-regulated M2-like genes, including TGF-13 and IL-10. However, several other 
genes that contribute to the alternatively activated phenotype, including MMP-9, 
MMP-12, and VEGF were significantly down-regulated, conducive to tumor 
regression, and further demonstrating that macrophages employ a spectrum of 
activation phenotypes rather than distinct subsets. Additionally, many studies 
have focused on the immunosuppressive effects of IL-10 in the tumor 
microenvironment, however I L -10 also exerts some immunostimulatory effects, 
such as activation of B cells, induction of cytotoxic T lymphocytes, and up-
regulation of genes in TLR-activated dendritic cells and macrophages [154-157]. 
IL-10 secretion from A-FABP deficient TIM may also be a contributing factor in 
reduced tumor growth and metastasis by influencing several other infiltrating 
immune cells. The effects of IL-10 in the A-FABP-I- tumor model is an ongoing 
effort in our lab. 
As mentioned previously, A-FABP deficiency is associated with increased 
PPAR-y activity [109]. PPAR-y has been shown to induce cell growth arrest, 
apoptosis, and differentiation in many cancer types including breast, lung, colon, 
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gastric, and prostate cancers [158, 159]. In immune cells, PPAR-y regulates 
inflammatory gene transcription. Several cytokines including IL-6 and TNF-o 
have been implicated in the progression of several types of cancer, and studies 
show that PPAR-y agonists, which have been shown to have therapeutic 
potential in the treatment of inflammatory and metabolic disease as well as 
cancer, can suppress the expression of these cytokines via inhibition of NF-KB or 
C/EBP~ [159, 160]. In our model, A-FABP deficiency down-regulates several 
inflammatory genes, which is likely due to PPAR-y-mediated transrepression of 
NF-KB. Activators of PPAR-y have also been shown to inhibit MMP-9 expression 
in human bronchial epithelial cells as well as MMP-12 in macrophages [161]. 
Furthermore, activation of PPAR-y represses VEGF expression in human 
endometrial cells and reduce serum VEGF levels in diet-induced insulin resistant 
mice [162, 163]. Thus, enhanced PPAR-y activation in TIMs from A-FABP 
deficient mice may also suppress MMP and VEGF expression in addition to other 
pro-inflammatory mediators, thereby contributing to reduced lung and liver 
metastasis and to tumor regression. Additionally, we have previously shown that 
PPAR-y up-regulates genes involved in cholesterol trafficking. Several published 
studies have demonstrated that tumor-infiltrating macrophages can take on a 
foam cell phenotype as seen in atherosclerosis [164]. In the diet-induced obese 
A-FABP deficient model, PPAR-y activation may allow for the transport of 
cholesterol out of the cell, thus contributing to anti-inflammation. 
We have also found that macrophages isolated from healthy A-FABP-I-
mice have increased levels of phosphorylated AMP-activated kinase 01, AMPK-
01 (data not shown). Additionally, we, and others, have found that in an obese 
state, AMPK, which also promotes anti-inflammatory gene expression, is down-
regulated while A-FABP expression levels are increased [165]. This phenomenon 
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may contribute to the polarized pro-inflammatory phenotype found in 
macrophages bathed in an environment of metabolic excess. AMPK is a 
metabolic sensor that, upon activation, inhibits energy-consuming processes and 
promote ATP-producing pathways [166]. AMPK activation has been shown to 
provide protection against tumor growth and metastasis in both mice and diabetic 
humans [167,168]. Moreover, the anti-diabetic drug, metformin, which has 
gained recent interest in the treatment of cancer, is a potent activator of AMPK. 
Because AMPK has been shown to suppress various proteins involved in 
metastasis, including MMP-9 [167, 169], it may also serve as an additional 
mechanism by which A-FABP deficiency suppresses tumor growth and 
metastasis in both lean and obese mice. Furthermore, both A-FABP deficiency 
and AMPK activation improves insulin sensitivity and reduces circulating levels of 
insulin, which may also contribute to tumor regression, particularly in diet-induced 
obese mice. 
Several studies have shown that tumor-infiltrating adipocytes display an 
activated phenotype and are capable of inducing cancer cell proliferation, 
migration, and invasion [170-172]. Neiman and colleagues further showed that 
the tumor-promoting functions of adipocytes could be attributed to A-FABP 
expression [144]. Because A-FABP is expressed in both adipocytes and 
macrophages, it is possible that the effect of A-FABP knockdown on tumor 
progression can be attributed to functions in both cell types, especially since we 
are using a whole animal knockout. In a model of atherosclerosis, Boord and 
colleagues conducted a bone marrow transplantation study to determine if the 
effects of A-FABP expression was due to its function in macrophages or 
adipocytes. When bone marrow from A-FABP-1-ApoE-1- mice were transferred into 
ApoE-1-mice, less atherosclerosis developed, suggesting that it was the 
73 
expression of A-FABP in macrophages and not adipocytes that contributed to 
disease progression [138]. This may also be the case in our LLl2 tumor model. 
With the recent development of macrophage-specific A-F ABP conditional 
knockout mice available at the Jackson Laboratory, this question can soon be 
addressed. 
In addition to adipocytes, dendritic cells, and macrophages, A-FABP has 
recently been shown to be expressed in endothelial cells of capillaries and small 
veins in both mouse and human tissue [173]. Studies illustrate that A-FABP 
expression is induced by treatment with VEGF-A and basic fibroblast growth 
factor (bFGF) via VEGF receptor-2 (VEGFR2). A-FABP knockdown in endothelial 
cells resulted in decreased proliferation of these cells in both untreated and 
VEGF-A- and bFGF-treated cells, suggesting that A-FABP induces endothelial 
cell proliferation via the VEGF-ANEGFR2 pathway [173]. Further studies 
demonstrated that chronic administration of an A-FABP inhibitor, BMS309403, 
improved endothelial cells dysfunction in ApoE deficient mice significantly [174]. 
Although no one has shown A-FABP expression in tumor-associated endothelial 
cells, it very well may be the case since protein expression in tumors are 
dysregulated. This is another avenue of the role of A-FABP in cancer progression 
to be explored. Inhibition of A-FABP would not only suppress the tumor-
promoting functions of macrophages and adipocytes, but it could possibly lead to 
a significant reduction in angiogenesis via inhibition of endothelial cell 
proliferation. 
In this study, we show a role of A-FABP in cancer progression, while 
deletion of this protein protects against tumor growth and metastasis. We also 
demonstrate the importance of A-FABP in the link between high fat consumption 
and cancer progression. Moreover, by using a lung cancer model, (past and 
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recent data suggests that obesity does not affect the development and 
advancement of lung cancer [175]) we were able to show that dietary conditions 
can impact the progression of this type of cancer. Our data, along with the finding 
that A-FABP deficiency is protective against atherosclerosis, insulin resistance, 
and type 2 diabetes, indicates that inhibition of A-FABP may be utilized as a 
novel approach in treating inflammatory and metabolic disorders, as well as 
cancer that is associated and unassociated with obesity. Moreover, because 
agonists of AMPK and PPAR-y have been implicated in cancer therapy, it may 
be more useful to inhibit A-FABP to activate AMPK and PPAR-y simultaneously, 
which may induce an enhanced therapeutic effect. 
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